

**This PANNA newsletter will also be available at the website: [www.pannastudy.com](http://www.pannastudy.com)**

A newsletter will be issued once per 3 months to update you on the status of the study and inclusions.

### Centres

All centres in *The Netherlands* are open for inclusion.

*Spain*: Badalona is open for inclusion.

*UK*: all centres are open for inclusion.

*Italy*: Rome is open for inclusion.

*Germany*: National Authority approval, documents have been submitted for ethics approval.

*Ireland*: submission done.

*Portugal*: working on submission.

*France*: working on submission.

*Belgium*: to be visited soon.

*Canada*: a grant has been assigned, ethics submission will start.

Other centres (*Switzerland; Poland*) will follow and will be contacted by Angela as soon as the above mentioned centres have started.

### List of compounds under investigation

#### panna

Etravirine, Intence, ETV  
Emtricitabine, Emtriva or FTC  
Tenofovir, Viread, TDF  
Atazanavir, Reyataz, ATV  
Fosamprenavir, Telzir, FPV  
Darunavir, Prezista, DRV  
Tipranavir, Aptivus, TPV  
Indinavir, Crixivan, IDV  
Raltegravir, Isentress, RAL  
Enfuvirtide, Fuzeon, T-20  
Maraviroc, Celsentri, MVC  
Efavirenz, Stocrin, EFV\*  
\*UK/Ireland only

### Amendment



A second amendment to the protocol has been written:

In case of the treatment with atazanavir/r 300/100mg QD an additional trough blood sample will be taken 12-16 weeks post partum.

To add the analysis of metabolites of the agents and to add investigators to the list. The amendment is being submitted to the ethics committees if applicable.

### Inclusions

14 subjects signed informed consent.



### IMPORTANT:

#### Next Investigators Meeting in Glasgow during Tenth International Congress on Drug Therapy in HIV Infection (7-11 November 2010)

We have requested a room to have the next investigators meeting. The date of the meeting is not yet known, but I will inform you asap.

See <http://www.hiv10.com/> for information on the conference.

Angela Colbers  
Project manager

E-mail: [A.Colbers@akf.umcn.nl](mailto:A.Colbers@akf.umcn.nl)  
[HIVPharmacology@akf.umcn.nl](mailto:HIVPharmacology@akf.umcn.nl)  
Radboud University Nijmegen Medical Centre, Internal postal code 864,  
Department of Clinical Pharmacy,  
P.O. Box 9101, 6500 HB Nijmegen

Phone: + 31 (0)24 - 361 64 05  
Fax: + 31 (0)24- 366 87 55